SchizophreniaNCT06515522
A Biological Signature for the Early Differential Diagnosis of Psychosis
An observational study of Schizophrenia and Bipolar Disorder, run by IRCCS San Raffaele.
Trial summary
Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden. Although they are identified as distinct disorders, the potential overlapping symptomatology poses important challenges for the differential diagnosis. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- What is being tested?
- differential diagnosis
- How many people
- 1,850 participants
- Where
- No sites listed yet
- Study dates
- 31 Aug 2024to Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Adult, Older adult
Study population: Psychiatric patients with a diagnosis of Schizophrenia or Bipolar disorder or Major depressive disorder, neuroimaging data and peripheral blood sampling. Healthy controls with neuroimaging data and peripheral blood sampling
Who may be able to join
- Aged 18-65
- diagnosed with Schizophrenia, Bipolar Disorder or Major depressive disorder.
- For Bipolar and Major depressive disorder, Hamilton Depression Rating Scale scores >8
- Multimodal 3 T MRI acquisition available (*)
- Genetic and serum inflammatory data available, or serum and whole blood available for genotyping and inflammatory markers determination.
Who cannot join
- Presence of major medical or neurological disorders
- Alcohol or drugs abuse or dependence
- Conditions known to alter immune-inflammatory status, such as rheumatic diseases, malignancies,
- ongoing treatment with drugs acting on the immune system, such as corticosteroids, NSAIDs and other immunomodulatory drugs.
- Pregnancy or lactating
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Biological Signature for the Early Differential Diagnosis of Psychosis: Unveiling the Differences Between Mood Disorders and Schizophrenia With Multimodal Machine Learning Techniques
Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden. Although they are identified as distinct disorders, the potential overlapping symptomatology poses important challenges for the differential diagnosis. A consistent literature affirms that brain structure, and function reflect an intermediate phenotype of an underlying genetic vulnerability for the disorders, shaped by interaction with environmental experiences. Such experiences include early life stress and trauma which seem to characterize psychiatric patients and have been associated with brain abnormalities. Further, early life experiences have been associated with inflammation in a subpopulation of psychiatric patients However imaging, inflammatory, and genetic group-level differences, albeit consistent, do not impact clinical practice since they have not been translated into individual prediction. To address these issues, a rapidly growing body of scientific literature implemented computational techniques, such as machine learning (ML). In this project we will develop cutting-edge ML algorithms to predict the differential diagnosis between mood disorders and SZ from genetic, neuroimaging, inflammatory and environmental data in a unique cohort of 1850 patients and 1000 healthy controls recruited in 4 different centers in Italy. The project will address three different aims: in aim 1 we will develop algorithms for the differential diagnosis between SZ and MD combining multimodal neuroimaging and genetic data; in aim 2 we will predict the differential diagnosis between SZ and MD from immuno-inflammatory and environmental data; finally, with aim three we will exploit an animal model to identify the underlying mechanisms of brain alterations associated with exposure to early life stress. Machine learning analyses will include algorithms for data harmonization and feature reduction, as well as for generating normative models. Finally. different classifying models will be compared considering the specific features to achieve the best performance.The definition of reliable and objective biomarkers, combined with cutting-edge computational methodology, could help clinicians in providing more precise diagnoses and early interventions, also considering dimensional constructs \& factors influencing outcomes such as affective vs non-affective psychosis and breadth of exposure to traumatic events
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Being tested
- differential diagnosis
- Medical subject headings
- Schizophrenia, Bipolar Disorder, Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
differential diagnosisOther
this is a retrospective observational study. no intervention has been or will be performed
| Study group | Role | What they receive |
|---|---|---|
| Schizophrenia | All patients with schizophrenia recruited from 2007 and 2023 Receives: Other: differential diagnosis | |
| Mood disorders | All patients with bipolar or major depressive disorders recruited from 2007 and 2023 Receives: Other: differential diagnosis | |
| Controls | healthy controls Receives: Other: differential diagnosis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Schizophrenia vs Mood disorders
Predicting the differential diagnosis between Schizophrenia and Mood Disorders combining multimodal neuroimaging, immuno-inflammatory and genetic data
Measured: baseline
Secondary outcomes (1)
Bipolar vs major depressive disorder
Predicting the differential diagnosis between major depression and bipolar disorder, and the presence or absence of psychotic symptoms combining multimodal neuroimaging, immuno-inflammatory and genetic data
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2024
- Study start31 Aug 2024 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by IRCCS San RaffaeleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,850 participants (estimated)
Sponsor and investigators
- Lead sponsor
- IRCCS San Raffaele
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Health, Italy
- Responsible party
- Principal investigator, Francesco Benedetti, IRCCS San Raffaele
- Investigators
- Francesco Benedetti, Prof, Principal investigator, IRCCS Ospedale San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06515522
- Sponsor's protocol ID
- PNRR-MCNT2-2023-12378015
- Status last verified
- Jul 2024
- First submitted
- 17 Jul 2024
- Last updated
- 23 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Biological Signature for the Early Differential Diagnosis of Psychosis: Unveiling the Differences Between Mood Disorders and Schizophrenia With Multimodal Machine Learning Techniques
- ClinicalTrials.gov ID
- NCT06515522
- Acronym / sponsor ID
- PNRR-MCNT2-2023-12378015
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,850 participants (estimated)
- Lead sponsor
- IRCCS San RaffaeleUniversity, hospital or other
- Collaborators
- Ministry of Health, Italy
- Study start
- 31 Aug 2024 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 23 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden. Although they are identified as distinct disorders, the potential overlapping symptomatology poses important challenges for the differential diagnosis. A consistent literature affirms that brain structure, and function reflect an intermediate phenotype of an underlying genetic vulnerability for the disorders, shaped by interaction with environmental experiences. Such experiences include early life stress and trauma which seem to characterize psychiatric patients and have been associated with brain abnormalities. Further, early life experiences have been associated with inflammation in a subpopulation of psychiatric patients However imaging, inflammatory, and genetic group-level differences, albeit consistent, do not impact clinical practice since they have not been translated into individual prediction. To address these issues, a rapidly growing body of scientific literature implemented computational techniques, such as machine learning (ML). In this project we will develop cutting-edge ML algorithms to predict the differential diagnosis between mood disorders and SZ from genetic, neuroimaging, inflammatory and environmental data in a unique cohort of 1850 patients and 1000 healthy controls recruited in 4 different centers in Italy. The project will address three different aims: in aim 1 we will develop algorithms for the differential diagnosis between SZ and MD combining multimodal neuroimaging and genetic data; in aim 2 we will predict the differential diagnosis between SZ and MD from immuno-inflammatory and environmental data; finally, with aim three we will exploit an animal model to identify the underlying mechanisms of brain alterations associated with exposure to early life stress. Machine learning analyses will include algorithms for data harmonization and feature reduction, as well as for generating normative models. Finally. different classifying models will be compared considering the specific features to achieve the best performance.The definition of reliable and objective biomarkers, combined with cutting-edge computational methodology, could help clinicians in providing more precise diagnoses and early interventions, also considering dimensional constructs \& factors influencing outcomes such as affective vs non-affective psychosis and breadth of exposure to traumatic events
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Schizophrenia | – | Other: differential diagnosisAll patients with schizophrenia recruited from 2007 and 2023 |
| Mood disorders | – | Other: differential diagnosisAll patients with bipolar or major depressive disorders recruited from 2007 and 2023 |
| Controls | – | Other: differential diagnosishealthy controls |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Psychiatric patients with a diagnosis of Schizophrenia or Bipolar disorder or Major depressive disorder, neuroimaging data and peripheral blood sampling. Healthy controls with neuroimaging data and peripheral blood sampling
Key inclusion criteria (5 listed)
- Aged 18-65
- diagnosed with Schizophrenia, Bipolar Disorder or Major depressive disorder.
- For Bipolar and Major depressive disorder, Hamilton Depression Rating Scale scores >8
- Multimodal 3 T MRI acquisition available (*)
- Genetic and serum inflammatory data available, or serum and whole blood available for genotyping and inflammatory markers determination.
Key exclusion criteria (5 listed)
- Presence of major medical or neurological disorders
- Alcohol or drugs abuse or dependence
- Conditions known to alter immune-inflammatory status, such as rheumatic diseases, malignancies,
- ongoing treatment with drugs acting on the immune system, such as corticosteroids, NSAIDs and other immunomodulatory drugs.
- Pregnancy or lactating
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| differential diagnosisthis is a retrospective observational study. no intervention has been or will be performed | Other | Controls, Mood disorders, Schizophrenia |
Primary outcome
Schizophrenia vs Mood disorders
Time frame: baseline
Predicting the differential diagnosis between Schizophrenia and Mood Disorders combining multimodal neuroimaging, immuno-inflammatory and genetic data
1 secondary outcome
Bipolar vs major depressive disorder
Time frame: baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2024.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francesco Benedetti, Prof principal investigator
IRCCS Ospedale San Raffaele
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia and Bipolar Disorder, run by IRCCS San Raffaele.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francesco Benedetti, Prof (00390226433156, benedetti.francesco@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Schizophrenia vs Mood disorders (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.